Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Live vaccine use and safety in DiGeorge syndrome.

Hofstetter AM, Jakob K, Klein NP, Dekker CL, Edwards KM, Halsey NA, Baxter R, Williams SE, Graham PL 3rd, LaRussa P.

Pediatrics. 2014 Apr;133(4):e946-54. doi: 10.1542/peds.2013-0831. Epub 2014 Mar 31.

2.

Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

Perez EE, Bokszczanin A, McDonald-McGinn D, Zackai EH, Sullivan KE.

Pediatrics. 2003 Oct;112(4):e325.

PMID:
14523220
3.

Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.

Nolan T, McIntyre P, Roberton D, Descamps D.

Vaccine. 2002 Dec 13;21(3-4):281-9.

PMID:
12450703
4.

Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.

Nolan T, Bernstein DI, Block SL, Hilty M, Keyserling HL, Marchant C, Marshall H, Richmond P, Yogev R, Cordova J, Cho I, Mendelman PM; LAIV Study Group.

Pediatrics. 2008 Mar;121(3):508-16. doi: 10.1542/peds.2007-1064.

PMID:
18310199
5.

Live attenuated measles, mumps, rubella, and varicella zoster virus vaccine (Priorix-Tetra).

Dhillon S, Curran MP.

Paediatr Drugs. 2008;10(5):337-47. Review.

PMID:
18754700
6.

Safety and immunogenicity of measles-mumps-rubella vaccine in children with congenital immunodeficiency (DiGeorge syndrome).

Azzari C, Gambineri E, Resti M, Moriondo M, Betti L, Saldias LR, G Gelli AM, Vierucci A.

Vaccine. 2005 Feb 25;23(14):1668-71.

PMID:
15705470
7.

Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States.

Pool V, Braun MM, Kelso JM, Mootrey G, Chen RT, Yunginger JW, Jacobson RM, Gargiullo PM; VAERS Team. US Vaccine Adverse Event Reporting System.

Pediatrics. 2002 Dec;110(6):e71.

PMID:
12456938
8.

Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age.

Rinderknecht S, Michaels MG, Blatter M, Gaglani M, Andrews W, Abughali N, Chandreshekaran V, Trofa AF.

Pediatr Infect Dis J. 2011 Oct;30(10):e179-85. doi: 10.1097/INF.0b013e31822256a5.

PMID:
21617573
9.

Simultaneous vaccination of Chinese applicants for a United States immigrant visa.

Hua L, Hongtao H, Shunqin W, Jinping G, Jiandong C, Zhaoliang L, Xinwen F.

Travel Med Infect Dis. 2008 May;6(3):130-6. doi: 10.1016/j.tmaid.2008.03.004.

PMID:
18486068
10.

Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children.

Vesikari T, Ohrling A, Baer M, Delem A, Bogaerts H, André FE.

Acta Paediatr Scand. 1991 Nov;80(11):1051-7.

PMID:
1661057
11.

Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.

Asatryan A, Pool V, Chen RT, Kohl KS, Davis RL, Iskander JK; VAERS team.

Vaccine. 2008 Feb 26;26(9):1166-72. doi: 10.1016/j.vaccine.2007.12.049. Epub 2008 Jan 22. Review.

PMID:
18255204
12.

Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations.

Heijstek MW, Ott de Bruin LM, Borrow R, van der Klis F, Koné-Paut I, Fasth A, Minden K, Ravelli A, Abinun M, Pileggi G, Borte M, Bijl M, Wulffraat NM.

Autoimmun Rev. 2011 Dec;11(2):112-22. doi: 10.1016/j.autrev.2011.08.010. Epub 2011 Aug 28. Review.

PMID:
21896342
13.

Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

Knuf M, Zepp F, Helm K, Maurer H, Prieler A, Kieninger-Baum D, Douha M, Willems P.

Eur J Pediatr. 2012 Mar;171(3):463-70. doi: 10.1007/s00431-011-1569-4. Epub 2011 Sep 21.

PMID:
21935584
14.

Measles, mumps and rubella: control by vaccination.

van Druten JA, de Boo T, Plantinga AD.

Dev Biol Stand. 1986;65:53-63.

PMID:
3556777
15.

Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.

Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT.

MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. Erratum in: MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(06):113.

16.

Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.

Parment PA, Svahn A, Rudén U, Bråkenhielm G, Storsaeter J, Akesson L, Linde A.

Scand J Infect Dis. 2003;35(10):736-42.

PMID:
14606613
17.
18.

An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.

Klein NP, Weston WM, Kuriyakose S, Kolhe D, Howe B, Friedland LR, Van Der Meeren O.

Vaccine. 2012 Jan 11;30(3):668-74. doi: 10.1016/j.vaccine.2011.10.065. Epub 2011 Nov 4.

PMID:
22064267
19.

Updated data on effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation.

Shinjoh M, Hoshino K, Takahashi T, Nakayama T.

Vaccine. 2015 Jan 29;33(5):701-7. doi: 10.1016/j.vaccine.2014.11.052. Epub 2014 Dec 13.

PMID:
25510391
20.

Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.

Ljungman P, Fridell E, Lönnqvist B, Bolme P, Böttiger M, Gahrton G, Linde A, Ringdén O, Wahren B.

J Infect Dis. 1989 Apr;159(4):610-5.

PMID:
2647859

Supplemental Content

Support Center